Click Here for 5% Off Your First Aladdin Purchase!
Call +1 (833) 552-7181 or Contact us Earn $25 in coupons on your first order with Aladdin!
Toggle Nav
My Cart
Search
Advanced Search
Menu
Sign In
྾
main product photo

Recombinant PLK1 Antibody - Primary antibody, specific to PLK1, Rabbit IgG

  • ExactAb™
  • Recombinant
  • Validated
  • 0.7 mg/mL
Features and benefits
  • Short Overview:

    Recombinant; Rabbit anti Human PLK1 Antibody; WB, ICC, IF; Unconjugated

  • Species reactivity(Reacts with): Human,Rat
  • Isotype: Rabbit IgG
    Application:
  • IF/ICC
  • WB
Item Number
Ab122369
Grouped product items
SKUSizeAvailabilityPrice Qty
Ab122369-10μl
10μl
In stock
$66.90
Ab122369-50μl
50μl
In stock
$189.90
Ab122369-100μl
100μl
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$299.90
Ab122369-1ml
1ml
Available within 8-12 weeks(?)
Production requires sourcing of materials. We appreciate your patience and understanding.
$2,809.90
Add to Wish List Compare
Bulk Order  DATASHEET

Recombinant; Rabbit anti Human PLK1 Antibody; WB, ICC, IF; Unconjugated

View related series
Accession#:P53350 Gene ID:5347 PLK1

Basic Description

Product NameRecombinant PLK1 Antibody - Primary antibody, specific to PLK1, Rabbit IgG
SynonymsCell cycle regulated protein kinase antibody; PLK 1 antibody; PLK antibody; PLK-1 antibody; plk1 antibody; PLK1_HUMAN antibody; Polo like kinase 1 antibody; Polo-like kinase 1 antibody; Serine/threonine protein kinase 13 antibody; Serine/threonine protein
Specifications & PurityExactAb™, Validated, Recombinant, 0.7 mg/mL
Host speciesRabbit
SpecificityPLK1
ImmunogenA synthetic peptide derived from human PLK1 (AA 455-474)
Positive ControlWB: Jurkat and Hep G2 cell lysates. ICC/IF: HeLa cells.
ConjugationUnconjugated
GradeExactAb™, Recombinant, Validated
Product Description

Rabbit anti Human PLK1 Antibody, Recombinant, could be used for WB, ICC, IF and so on.
Application:
WB: 1/500-1/2000
ICC/IF: 1/50-1/200
Protein Function
Serine/threonine-protein kinase that performs several important functions throughout M phase of the cell cycle, including the regulation of centrosome maturation and spindle assembly, the removal of cohesins from chromosome arms, the inactivation of APC/C inhibitors, and the regulation of mitotic exit and cytokinesis. Required for recovery after DNA damage checkpoint and entry into mitosis. Required for kinetochore localization of BUB1B. Phosphorylates SGOL1. Required for spindle pole localization of isoform 3 of SGOL1 and plays a role in regulating its centriole cohesion function. Phosphorylates BORA, and thereby promotes the degradation of BORA. Contributes to the regulation of AURKA function. Regulates TP53 stability through phosphorylation of TOPORS.

Product Properties

IsotypeRabbit IgG
SDS-PAGE150 kDa
Purification MethodAntigen affinity purified
FormLiquid
Concentration0.7 mg/mL
Storage TempStore at -20°C,Avoid repeated freezing and thawing
Shipped InIce chest + Ice pads
Stability And StorageStore at 4°C short term (1-2 weeks). Store at -20°C long term (24 months). Upon delivery aliquot. Avoid freeze/thaw cycle.

Images

Recombinant PLK1 Antibody (Ab122369) - Western Blot
All lanes: Recombinant PLK1 Antibody (Ab122369) at 1/2000 dilution
Samples: Lysates at 20 µg per lane
Secondary: Goat Anti-Rabbit IgG H&L (HRP) (Ab170144) at 1/20000 dilution

Predicted band size: 68 kDa
Observed band size: 65 kDa
Exposure time: 149.4 s

Recombinant PLK1 Antibody (Ab122369) - IF/ICC
Immunocytochemistry analysis of PLK1 (green) in HeLa using Recombinant PLK1 Antibody (Ab122369), and cells were counterstained with DAPI (blue).


Associated Targets

PLK1 Tchem Serine/threonine-protein kinase PLK1 0 Activities

Activity TypeActivity Value -log(M)Mechanism of ActionActivity ReferencePublications (PubMed IDs)

Application

ApplicationDilution info
WB

1/500-1/2000

ICC/IF

1/50-1/200

Certificates

Certificate of Analysis(COA)

Enter Lot Number to search for COA:

To view the certificate results,please click on a Lot number.For Lot numbers from past orders,please use our order status section

2 results found

Lot NumberCertificate TypeDateItem
ZJ24F0303421Certificate of AnalysisMar 20, 2024 Ab122369
ZJ24F0303422Certificate of AnalysisMar 20, 2024 Ab122369

Related Documents

 SDS

 Specification Sheet

FAQs and Articles

FAQ
In-cell ELISA protocol
Categories: Protocols
Tags:
Monoclonal antibodies In-cell ELISA Cytoblot Protein quantification HRP-Conjugated Secondary Antibodies Polyclonal Antibodies

References

1. Huber K, Brault L, Fedorov O, Gasser C, Filippakopoulos P, Bullock AN, Fabbro D, Trappe J, Schwaller J, Knapp S et al..  (2012)  7,8-dichloro-1-oxo-β-carbolines as a versatile scaffold for the development of potent and selective kinase inhibitors with unusual binding modes..  J Med Chem,  55  (1): (403-13).  [PMID:22136433]
2. Whelligan DK, Solanki S, Taylor D, Thomson DW, Cheung KM, Boxall K, Mas-Droux C, Barillari C, Burns S, Grummitt CG et al..  (2010)  Aminopyrazine inhibitors binding to an unusual inactive conformation of the mitotic kinase Nek2: SAR and structural characterization..  J Med Chem,  53  (21): (7682-98).  [PMID:20936789]
3. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, Davies H, Teague J, Butler A, Stevens C et al..  (2007)  Patterns of somatic mutation in human cancer genomes..  Nature,  446  (7132): (153-8).  [PMID:17344846]
4. Szczepankiewicz BG, Kosogof C, Nelson LT, Liu G, Liu B, Zhao H, Serby MD, Xin Z, Liu M, Gum RJ et al..  (2006)  Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity..  J Med Chem,  49  (12): (3563-80).  [PMID:16759099]
5. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krssák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J et al..  (2007)  BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo..  Curr Biol,  17  (4): (316-22).  [PMID:17291758]
6. Aston NM, Bamborough P, Buckton JB, Edwards CD, Holmes DS, Jones KL, Patel VK, Smee PA, Somers DO, Vitulli G et al..  (2009)  p38alpha mitogen-activated protein kinase inhibitors: optimization of a series of biphenylamides to give a molecule suitable for clinical progression..  J Med Chem,  52  (20): (6257-69).  [PMID:19772287]
7. Guagnano V, Furet P, Spanka C, Bordas V, Le Douget M, Stamm C, Brueggen J, Jensen MR, Schnell C, Schmid H et al..  (2011)  Discovery of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea (NVP-BGJ398), a potent and selective inhibitor of the fibroblast growth factor receptor family of receptor tyrosine kinase..  J Med Chem,  54  (20): (7066-83).  [PMID:21936542]
8. Rowbottom MW, Faraoni R, Chao Q, Campbell BT, Lai AG, Setti E, Ezawa M, Sprankle KG, Abraham S, Tran L et al..  (2012)  Identification of 1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)urea hydrochloride (CEP-32496), a highly potent and orally efficacious inhibitor of V-RAF murine sarcoma viral oncogene homologue B1 (BRAF) V600E..  J Med Chem,  55  (3): (1082-105).  [PMID:22168626]
9. Fancelli D, Moll J, Varasi M, Bravo R, Artico R, Berta D, Bindi S, Cameron A, Candiani I, Cappella P et al..  (2006)  1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazoles: identification of a potent Aurora kinase inhibitor with a favorable antitumor kinase inhibition profile..  J Med Chem,  49  (24): (7247-51).  [PMID:17125279]
10. Apsel B, Blair JA, Gonzalez B, Nazif TM, Feldman ME, Aizenstein B, Hoffman R, Williams RL, Shokat KM, Knight ZA.  (2008)  Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases..  Nat Chem Biol,  4  (11): (691-9).  [PMID:18849971]
11. Doe C, Bentley R, Behm DJ, Lafferty R, Stavenger R, Jung D, Bamford M, Panchal T, Grygielko E, Wright LL et al..  (2007)  Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities..  J Pharmacol Exp Ther,  320  (1): (89-98).  [PMID:17018693]
12. Zarrinkar PP, Gunawardane RN, Cramer MD, Gardner MF, Brigham D, Belli B, Karaman MW, Pratz KW, Pallares G, Chao Q et al..  (2009)  AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)..  Blood,  114  (14): (2984-92).  [PMID:19654408]
13. Conway JG, McDonald B, Parham J, Keith B, Rusnak DW, Shaw E, Jansen M, Lin P, Payne A, Crosby RM et al..  (2005)  Inhibition of colony-stimulating-factor-1 signaling in vivo with the orally bioavailable cFMS kinase inhibitor GW2580..  Proc Natl Acad Sci USA,  102  (44): (16078-83).  [PMID:16249345]
14. Gilmartin AG, Bleam MR, Richter MC, Erskine SG, Kruger RG, Madden L, Hassler DF, Smith GK, Gontarek RR, Courtney MP et al..  (2009)  Distinct concentration-dependent effects of the polo-like kinase 1-specific inhibitor GSK461364A, including differential effect on apoptosis..  Cancer Res,  69  (17): (6969-77).  [PMID:19690138]
15. Sampson PB, Liu Y, Patel NK, Feher M, Forrest B, Li SW, Edwards L, Laufer R, Lang Y, Ban F et al..  (2015)  The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents..  J Med Chem,  58  (1): (130-46).  [PMID:24867403]
16. Lafleur K, Huang D, Zhou T, Caflisch A, Nevado C.  (2009)  Structure-based optimization of potent and selective inhibitors of the tyrosine kinase erythropoietin producing human hepatocellular carcinoma receptor B4 (EphB4)..  J Med Chem,  52  (20): (6433-46).  [PMID:19788238]
17. Henise JC, Taunton J.  (2011)  Irreversible Nek2 kinase inhibitors with cellular activity..  J Med Chem,  54  (12): (4133-46).  [PMID:21627121]
18. Okuzumi T, Fiedler D, Zhang C, Gray DC, Aizenstein B, Hoffman R, Shokat KM.  (2009)  Inhibitor hijacking of Akt activation..  Nat Chem Biol,  5  (7): (484-93).  [PMID:19465931]
19. Papeo G, Posteri H, Borghi D, Busel AA, Caprera F, Casale E, Ciomei M, Cirla A, Corti E, D'Anello M et al..  (2015)  Discovery of 2-[1-(4,4-Difluorocyclohexyl)piperidin-4-yl]-6-fluoro-3-oxo-2,3-dihydro-1H-isoindole-4-carboxamide (NMS-P118): A Potent, Orally Available, and Highly Selective PARP-1 Inhibitor for Cancer Therapy..  J Med Chem,  58  (17): (6875-98).  [PMID:26222319]
20. Bravo-Altamirano K, George KM, Frantz MC, Lavalle CR, Tandon M, Leimgruber S, Sharlow ER, Lazo JS, Wang QJ, Wipf P.  (2011)  Synthesis and Structure-Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D..  ACS Med Chem Lett,  2  (2): (154-159).  [PMID:21617763]
21. Aronov AM, Tang Q, Martinez-Botella G, Bemis GW, Cao J, Chen G, Ewing NP, Ford PJ, Germann UA, Green J et al..  (2009)  Structure-guided design of potent and selective pyrimidylpyrrole inhibitors of extracellular signal-regulated kinase (ERK) using conformational control..  J Med Chem,  52  (20): (6362-8).  [PMID:19827834]
22. Kim KH, Maderna A, Schnute ME, Hegen M, Mohan S, Miyashiro J, Lin L, Li E, Keegan S, Lussier J et al..  (2011)  Imidazo[1,5-a]quinoxalines as irreversible BTK inhibitors for the treatment of rheumatoid arthritis..  Bioorg Med Chem Lett,  21  (21): (6258-63).  [PMID:21958547]
23. Hobson AD, Harris CM, van der Kam EL, Turner SC, Abibi A, Aguirre AL, Bousquet P, Kebede T, Konopacki DB, Gintant G et al..  (2015)  Discovery of A-971432, An Orally Bioavailable Selective Sphingosine-1-Phosphate Receptor 5 (S1P5) Agonist for the Potential Treatment of Neurodegenerative Disorders..  J Med Chem,  58  (23): (9154-70).  [PMID:26509640]
24. Tan L, Gurbani D, Weisberg EL, Jones DS, Rao S, Singer WD, Bernard FM, Mowafy S, Jenney A, Du G et al..  (2017)  Studies of TAK1-centered polypharmacology with novel covalent TAK1 inhibitors..  Bioorg Med Chem,  25  (4): (1320-1328).  [PMID:28038940]
25. Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, Ding Y, Tamez V, Zhang Y, Mathur M et al..  (2015)  Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a Potent and Selective Proviral Insertion Site of Moloney Murine Leukemia (PIM) 1, 2, and 3 Kinase Inhibitor in Clinical Trials for Hematological Malignancies..  J Med Chem,  58  (21): (8373-86).  [PMID:26505898]
26. Pippione AC, Sainas S, Federico A, Lupino E, Piccinini M, Kubbutat M, Contreras JM, Morice C, Barge A, Ducime A et al..  (2018)  N-Acetyl-3-aminopyrazoles block the non-canonical NF-kB cascade by selectively inhibiting NIK..  Medchemcomm,  9  (6): (963-968).  [PMID:30108985]
27. Patel S, Harris SF, Gibbons P, Deshmukh G, Gustafson A, Kellar T, Lin H, Liu X, Liu Y, Liu Y et al..  (2015)  Scaffold-Hopping and Structure-Based Discovery of Potent, Selective, And Brain Penetrant N-(1H-Pyrazol-3-yl)pyridin-2-amine Inhibitors of Dual Leucine Zipper Kinase (DLK, MAP3K12)..  J Med Chem,  58  (20): (8182-99).  [PMID:26431428]
28. Liu S, Yosief HO, Dai L, Huang H, Dhawan G, Zhang X, Muthengi AM, Roberts J, Buckley DL, Perry JA et al..  (2018)  Structure-Guided Design and Development of Potent and Selective Dual Bromodomain 4 (BRD4)/Polo-like Kinase 1 (PLK1) Inhibitors..  J Med Chem,  61  (17): (7785-7795).  [PMID:30125504]
29. Czako B, Marszalek JR, Burke JP, Mandal P, Leonard PG, Cross JB, Mseeh F, Jiang Y, Chang EQ, Suzuki E et al..  (2020)  Discovery of IACS-9439, a Potent, Exquisitely Selective, and Orally Bioavailable Inhibitor of CSF1R..  J Med Chem,  129  (3): (589-97).  [PMID:32787110]
30. Yin L, Li H, Liu W, Yao Z, Cheng Z, Zhang H, Zou H.  (2018)  A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy..  Eur J Med Chem,  144  (3): (1-28).  [PMID:29247857]
31. Erki Enkvist, Darja Lavogina, Gerda Raidaru, Angela Vaasa, Indrek Viil, Marje Lust, Kaido Viht, Asko Uri,.  (2006-11-28)  Conjugation of adenosine and hexa-(D-arginine) leads to a nanomolar bisubstrate-analog inhibitor of basophilic protein kinases..  Journal of medicinal chemistry,  49  ((24)): ( 7150-7159 ).  [PMID:17125267]
32. Seunghee Hong,Jinhee Kim,Sun-Mi Yun,Hyunseung Lee,Yoonsu Park,Soon-Sun Hong,Sungwoo Hong.  (2013-04-23)  Discovery of new benzothiazole-based inhibitors of breakpoint cluster region-Abelson kinase including the T315I mutant..  Journal of medicinal chemistry,  56  ((9)): (3531-3545).  [PMID:23600806]
33. Ajit Dhananjay Jagtap,Pei-Teh Chang,Jia-Rong Liu,Hsiao-Chun Wang,Nagendra B Kondekar,Li-Jiuan Shen,Hsiang-Wen Tseng,Grace Shiahuy Chen,Ji-Wang Chern.  (2014-08-05)  Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia..  European journal of medicinal chemistry,  85  (268-288).  [PMID:25089810]
34. Pevarello P, Brasca MG, Amici R, Orsini P, Traquandi G, Corti L, Piutti C, Sansonna P, Villa M, Pierce BS, Pulici M, Giordano P, Martina K, Fritzen EL, Nugent RA, Casale E, Cameron A, Ciomei M, Roletto F, Isacchi A, Fogliatto G, Pesenti E, Pastori W, Marsiglio A, Leach KL, Clare PM, Fiorentini F, Varasi M, Vulpetti A, Warpehoski MA..  (2004)  3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding..  J Med Chem,  47  (13): (3367-3380).  [PMID:15189033]
35. Zhao H, Serby MD, Xin Z, Szczepankiewicz BG, Liu M, Kosogof C, Liu B, Nelson LT, Johnson EF, Wang S, Pederson T, Gum RJ, Clampit JE, Haasch DL, Abad-Zapatero C, Fry EH, Rondinone C, Trevillyan JM, Sham HL, Liu G..  (2006)  Discovery of potent, highly selective, and orally bioavailable pyridine carboxamide c-Jun NH2-terminal kinase inhibitors..  J Med Chem,  49  (15): (4455-4458).  [PMID:16854050]
36. Feng Y, Yin Y, Weiser A, Griffin E, Cameron MD, Lin L, Ruiz C, Schürer SC, Inoue T, Rao PV, Schröter T, Lograsso P..  (2008)  Discovery of substituted 4-(pyrazol-4-yl)-phenylbenzodioxane-2-carboxamides as potent and highly selective Rho kinase (ROCK-II) inhibitors..  J Med Chem,  51  (21): (6642-6645).  [PMID:18834107]
37. Cole DC, Asselin M, Brennan A, Czerwinski R, Ellingboe JW, Fitz L, Greco R, Huang X, Joseph-McCarthy D, Kelly MF, Kirisits M, Lee J, Li Y, Morgan P, Stock JR, Tsao DH, Wissner A, Yang X, Chaudhary D..  (2008)  Identification, characterization and initial hit-to-lead optimization of a series of 4-arylamino-3-pyridinecarbonitrile as protein kinase C theta (PKCtheta) inhibitors..  J Med Chem,  51  (19): (5958-5963).  [PMID:18783200]
38. Park BS, El-Deeb IM, Yoo KH, Oh CH, Cho SJ, Han DK, Lee HS, Lee JY, Lee SH..  (2009)  Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor..  Bioorg Med Chem Lett,  19  (16): (4720-4723).  [PMID:19596575]
39. Li J, Kaoud TS, Laroche C, Dalby KN, Kerwin SM..  (2009)  Synthesis and biological evaluation of p38alpha kinase-targeting dialkynylimidazoles..  Bioorg Med Chem Lett,  19  (22): (6293-6297).  [PMID:19822424]
40. Shomin CD, Meyer SC, Ghosh I..  (2009)  Staurosporine tethered peptide ligands that target cAMP-dependent protein kinase (PKA): optimization and selectivity profiling..  Bioorg Med Chem,  17  (17): (6196-6202).  [PMID:19674907]
41. Wee XK, Yeo WK, Zhang B, Tan VB, Lim KM, Tay TE, Go ML..  (2009)  Synthesis and evaluation of functionalized isoindigos as antiproliferative agents..  Bioorg Med Chem,  17  (21): (7562-7571).  [PMID:19783149]
42. Egert-Schmidt AM, Dreher J, Dunkel U, Kohfeld S, Preu L, Weber H, Ehlert JE, Mutschler B, Totzke F, Schächtele C, Kubbutat MH, Baumann K, Kunick C..  (2010)  Identification of 2-anilino-9-methoxy-5,7-dihydro-6H-pyrimido[5,4-d][1]benzazepin-6-ones as dual PLK1/VEGF-R2 kinase inhibitor chemotypes by structure-based lead generation..  J Med Chem,  53  (6): (2433-2442).  [PMID:20170163]
43. Qiao L, Choi S, Case A, Gainer TG, Seyb K, Glicksman MA, Lo DC, Stein RL, Cuny GD..  (2009)  Structure-activity relationship study of EphB3 receptor tyrosine kinase inhibitors..  Bioorg Med Chem Lett,  19  (21): (6122-6126).  [PMID:19783434]
44. Lesuisse D, Dutruc-Rosset G, Tiraboschi G, Dreyer MK, Maignan S, Chevalier A, Halley F, Bertrand P, Burgevin MC, Quarteronet D, Rooney T..  (2010)  Rational design of potent GSK3beta inhibitors with selectivity for Cdk1 and Cdk2..  Bioorg Med Chem Lett,  20  (6): (1985-1989).  [PMID:20167481]
45. Yu H, Jung Y, Kim H, Lee J, Oh CH, Yoo KH, Sim T, Hah JM..  (2010)  1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors..  Bioorg Med Chem Lett,  20  (12): (3805-3808).  [PMID:20466542]
46. Deng X, Lim SM, Zhang J, Gray NS..  (2010)  Broad spectrum alkynyl inhibitors of T315I Bcr-Abl..  Bioorg Med Chem Lett,  20  (14): (4196-4200).  [PMID:20541934]
47. Mahboobi S, Sellmer A, Winkler M, Eichhorn E, Pongratz H, Ciossek T, Baer T, Maier T, Beckers T..  (2010)  Novel chimeric histone deacetylase inhibitors: a series of lapatinib hybrides as potent inhibitors of epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and histone deacetylase activity..  J Med Chem,  53  (24): (8546-8555).  [PMID:21080629]
48. Probst GD, Bowers S, Sealy JM, Truong AP, Hom RK, Galemmo RA, Konradi AW, Sham HL, Quincy DA, Pan H, Yao N, Lin M, Tóth G, Artis DR, Zmolek W, Wong K, Qin A, Lorentzen C, Nakamura DF, Quinn KP, Sauer JM, Powell K, Ruslim L, Wright S, Chereau D, Ren Z, Anderson JP, Bard F, Yednock TA, Griswold-Prenner I..  (2011)  Highly selective c-Jun N-terminal kinase (JNK) 2 and 3 inhibitors with in vitro CNS-like pharmacokinetic properties prevent neurodegeneration..  Bioorg Med Chem Lett,  21  (1): (315-319).  [PMID:21112785]
49. Kim MH, Kim M, Yu H, Kim H, Yoo KH, Sim T, Hah JM..  (2011)  Structure based design and syntheses of amino-1H-pyrazole amide derivatives as selective Raf kinase inhibitors in melanoma cells..  Bioorg Med Chem,  19  (6): (1915-1923).  [PMID:21353571]
50. Lesuisse D, Mauger J, Nemecek C, Maignan S, Boiziau J, Harlow G, Hittinger A, Ruf S, Strobel H, Nair A, Ritter K, Malleron JL, Dagallier A, El-Ahmad Y, Guilloteau JP, Guizani H, Bouchard H, Venot C..  (2011)  Discovery of the first non-ATP competitive IGF-1R kinase inhibitors: advantages in comparison with competitive inhibitors..  Bioorg Med Chem Lett,  21  (8): (2224-2228).  [PMID:21441024]
51. Ebada SS, Schulz B, Wray V, Totzke F, Kubbutat MH, Müller WE, Hamacher A, Kassack MU, Lin W, Proksch P..  (2011)  Arthrinins A-D: novel diterpenoids and further constituents from the sponge derived fungus Arthrinium sp..  Bioorg Med Chem,  19  (15): (4644-4651).  [PMID:21741249]
52. Kim H, Kim M, Lee J, Yu H, Hah JM..  (2011)  Syntheses of phenylpyrazolodiazepin-7-ones as conformationally rigid analogs of aminopyrazole amide scaffold and their antiproliferative effects on cancer cells..  Bioorg Med Chem,  19  (22): (6760-6767).  [PMID:22014755]
53. Ishikawa T, Seto M, Banno H, Kawakita Y, Oorui M, Taniguchi T, Ohta Y, Tamura T, Nakayama A, Miki H, Kamiguchi H, Tanaka T, Habuka N, Sogabe S, Yano J, Aertgeerts K, Kamiyama K..  (2011)  Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold..  J Med Chem,  54  (23): (8030-8050).  [PMID:22003817]
54. Caruso M, Valsasina B, Ballinari D, Bertrand J, Brasca MG, Caldarelli M, Cappella P, Fiorentini F, Gianellini LM, Scolaro A, Beria I..  (2012)  5-(2-amino-pyrimidin-4-yl)-1H-pyrrole and 2-(2-amino-pyrimidin-4-yl)-1,5,6,7-tetrahydro-pyrrolo[3,2-c]pyridin-4-one derivatives as new classes of selective and orally available Polo-like kinase 1 inhibitors..  Bioorg Med Chem Lett,  22  (1): (96-101).  [PMID:22154349]
55. Cuny GD, Ulyanova NP, Patnaik D, Liu JF, Lin X, Auerbach K, Ray SS, Xian J, Glicksman MA, Stein RL, Higgins JM..  (2012)  Structure-activity relationship study of beta-carboline derivatives as haspin kinase inhibitors..  Bioorg Med Chem Lett,  22  (5): (2015-2019).  [PMID:22335895]
56. Zhang J, Deng X, Choi HG, Alessi DR, Gray NS..  (2012)  Characterization of TAE684 as a potent LRRK2 kinase inhibitor..  Bioorg Med Chem Lett,  22  (5): (1864-1869).  [PMID:22335897]
57. Innocenti P, Cheung KM, Solanki S, Mas-Droux C, Rowan F, Yeoh S, Boxall K, Westlake M, Pickard L, Hardy T, Baxter JE, Aherne GW, Bayliss R, Fry AM, Hoelder S..  (2012)  Design of potent and selective hybrid inhibitors of the mitotic kinase Nek2: structure-activity relationship, structural biology, and cellular activity..  J Med Chem,  55  (7): (3228-3241).  [PMID:22404346]
58. Li WW, Wang XY, Zheng RL, Yan HX, Cao ZX, Zhong L, Wang ZR, Ji P, Yang LL, Wang LJ, Xu Y, Liu JJ, Yang J, Zhang CH, Ma S, Feng S, Sun QZ, Wei YQ, Yang SY..  (2012)  Discovery of the novel potent and selective FLT3 inhibitor 1-{5-[7-(3- morpholinopropoxy)quinazolin-4-ylthio]-[1,3,4]thiadiazol-2-yl}-3-p-tolylurea and its anti-acute myeloid leukemia (AML) activities in vitro and in vivo..  J Med Chem,  55  (8): (3852-3866).  [PMID:22452518]
59. Lo Monte F, Kramer T, Gu J, Anumala UR, Marinelli L, La Pietra V, Novellino E, Franco B, Demedts D, Van Leuven F, Fuertes A, Dominguez JM, Plotkin B, Eldar-Finkelman H, Schmidt B..  (2012)  Identification of glycogen synthase kinase-3 inhibitors with a selective sting for glycogen synthase kinase-3α..  J Med Chem,  55  (9): (4407-4424).  [PMID:22533818]
60. Lawrence HR, Martin MP, Luo Y, Pireddu R, Yang H, Gevariya H, Ozcan S, Zhu JY, Kendig R, Rodriguez M, Elias R, Cheng JQ, Sebti SM, Schonbrunn E, Lawrence NJ..  (2012)  Development of o-chlorophenyl substituted pyrimidines as exceptionally potent aurora kinase inhibitors..  J Med Chem,  55  (17): (7392-7416).  [PMID:22803810]
61. Reith AD, Bamborough P, Jandu K, Andreotti D, Mensah L, Dossang P, Choi HG, Deng X, Zhang J, Alessi DR, Gray NS..  (2012)  GSK2578215A; a potent and highly selective 2-arylmethyloxy-5-substitutent-N-arylbenzamide LRRK2 kinase inhibitor..  Bioorg Med Chem Lett,  22  (17): (5625-5629).  [PMID:22863203]
62. Amombo GM, Kramer T, Lo Monte F, Göring S, Fach M, Smith S, Kolb S, Schubenel R, Baumann K, Schmidt B..  (2012)  Modification of a promiscuous inhibitor shifts the inhibition from γ-secretase to FLT-3..  Bioorg Med Chem Lett,  22  (24): (7634-7640).  [PMID:23107479]
63. Shen S, Liu D, Wei C, Proksch P, Lin W..  (2012)  Purpuroines A-J, halogenated alkaloids from the sponge Iotrochota purpurea with antibiotic activity and regulation of tyrosine kinases..  Bioorg Med Chem,  20  (24): (6924-6928).  [PMID:23131412]
64. Mita Y, Noguchi-Yachide T, Ishikawa M, Hashimoto Y..  (2013)  Small-molecular, non-peptide, non-ATP-competitive polo-like kinase 1 (Plk1) inhibitors with a terphenyl skeleton..  Bioorg Med Chem,  21  (3): (608-617).  [PMID:23276450]
65. Garofalo AW, Adler M, Aubele DL, Bowers S, Franzini M, Goldbach E, Lorentzen C, Neitz RJ, Probst GD, Quinn KP, Santiago P, Sham HL, Tam D, Truong AP, Ye XM, Ren Z..  (2013)  Novel cinnoline-based inhibitors of LRRK2 kinase activity..  Bioorg Med Chem Lett,  23  (1): (71-74).  [PMID:23219325]
66. Yang LL, Li GB, Ma S, Zou C, Zhou S, Sun QZ, Cheng C, Chen X, Wang LJ, Feng S, Li LL, Yang SY..  (2013)  Structure-activity relationship studies of pyrazolo[3,4-d]pyrimidine derivatives leading to the discovery of a novel multikinase inhibitor that potently inhibits FLT3 and VEGFR2 and evaluation of its activity against acute myeloid leukemia in vitro and in vivo..  J Med Chem,  56  (4): (1641-1655).  [PMID:23362959]
67. Dolečková I, Cesnek M, Dračinský M, Brynda J, Voller J, Janeba Z, Kryštof V..  (2013)  Synthesis and biological evaluation of guanidino analogues of roscovitine..  Eur J Med Chem,  62  (443-452).  [PMID:23399722]
68. Brown A, Shi Q, Moore TW, Yoon Y, Prussia A, Maddox C, Liotta DC, Shim H, Snyder JP..  (2013)  Monocarbonyl curcumin analogues: heterocyclic pleiotropic kinase inhibitors that mediate anticancer properties..  J Med Chem,  56  (9): (3456-3466).  [PMID:23550937]
69. Mortensen DS, Sapienza J, Lee BG, Perrin-Ninkovic SM, Harris R, Shevlin G, Parnes JS, Whitefield B, Hickman M, Khambatta G, Bisonette RR, Peng S, Gamez JC, Leisten J, Narla RK, Fultz KE, Sankar S..  (2013)  Use of core modification in the discovery of CC214-2, an orally available, selective inhibitor of mTOR kinase..  Bioorg Med Chem Lett,  23  (6): (1588-1591).  [PMID:23414803]
70. Garofalo AW, Adler M, Aubele DL, Brigham EF, Chian D, Franzini M, Goldbach E, Kwong GT, Motter R, Probst GD, Quinn KP, Ruslim L, Sham HL, Tam D, Tanaka P, Truong AP, Ye XM, Ren Z..  (2013)  Discovery of 4-alkylamino-7-aryl-3-cyanoquinoline LRRK2 kinase inhibitors..  Bioorg Med Chem Lett,  23  (7): (1974-1977).  [PMID:23453068]
71. Franzini M, Ye XM, Adler M, Aubele DL, Garofalo AW, Gauby S, Goldbach E, Probst GD, Quinn KP, Santiago P, Sham HL, Tam D, Truong A, Ren Z..  (2013)  Triazolopyridazine LRRK2 kinase inhibitors..  Bioorg Med Chem Lett,  23  (7): (1967-1973).  [PMID:23454015]
72. Kusakabe K, Ide N, Daigo Y, Tachibana Y, Itoh T, Yamamoto T, Hashizume H, Hato Y, Higashino K, Okano Y, Sato Y, Inoue M, Iguchi M, Kanazawa T, Ishioka Y, Dohi K, Kido Y, Sakamoto S, Yasuo K, Maeda M, Higaki M, Ueda K, Yoshizawa H, Baba Y, Shiota T, Murai H, Nakamura Y..  (2013)  Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125)..  J Med Chem,  56  (11): (4343-4356).  [PMID:23634759]
73. Bowers S, Truong AP, Ye M, Aubele DL, Sealy JM, Neitz RJ, Hom RK, Chan W, Dappen MS, Galemmo RA, Konradi AW, Sham HL, Zhu YL, Beroza P, Tonn G, Zhang H, Hoffman J, Motter R, Fauss D, Tanaka P, Bova MP, Ren Z, Tam D, Ruslim L, Baker J, Pandya D, Diep L, Fitzgerald K, Artis DR, Anderson JP, Bergeron M..  (2013)  Design and synthesis of highly selective, orally active Polo-like kinase-2 (Plk-2) inhibitors..  Bioorg Med Chem Lett,  23  (9): (2743-2749).  [PMID:23522834]
74. Li J, Hu H, Lang Q, Zhang H, Huang Q, Wu Y, Yu L..  (2013)  A thienopyrimidine derivative induces growth inhibition and apoptosis in human cancer cell lines via inhibiting Aurora B kinase activity..  Eur J Med Chem,  65  (151-157).  [PMID:23707920]
75. Naud S, Westwood IM, Faisal A, Sheldrake P, Bavetsias V, Atrash B, Cheung KM, Liu M, Hayes A, Schmitt J, Wood A, Choi V, Boxall K, Mak G, Gurden M, Valenti M, de Haven Brandon A, Henley A, Baker R, McAndrew C, Matijssen B, Burke R, Hoelder S, Eccles SA, Raynaud FI, Linardopoulos S, van Montfort RL, Blagg J..  (2013)  Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1)..  J Med Chem,  56  (24): (10045-10065).  [PMID:24256217]
76. Blake JF, Gaudino JJ, De Meese J, Mohr P, Chicarelli M, Tian H, Garrey R, Thomas A, Siedem CS, Welch MB, Kolakowski G, Kaus R, Burkard M, Martinson M, Chen H, Dean B, Dudley DA, Gould SE, Pacheco P, Shahidi-Latham S, Wang W, West K, Yin J, Moffat J, Schwarz JB..  (2014)  Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2..  Bioorg Med Chem Lett,  24  (12): (2635-2639).  [PMID:24813737]
77. Xie F, Zhu H, Zhang H, Lang Q, Tang L, Huang Q, Yu L..  (2015)  In vitro and in vivo characterization of a benzofuran derivative, a potential anticancer agent, as a novel Aurora B kinase inhibitor..  Eur J Med Chem,  89  (310-319).  [PMID:25462247]
78. Horbert R, Pinchuk B, Johannes E, Schlosser J, Schmidt D, Cappel D, Totzke F, Schächtele C, Peifer C..  (2015)  Optimization of potent DFG-in inhibitors of platelet derived growth factor receptorβ (PDGF-Rβ) guided by water thermodynamics..  J Med Chem,  58  (1): (170-182).  [PMID:25007344]
79. Sampson PB, Liu Y, Forrest B, Cumming G, Li SW, Patel NK, Edwards L, Laufer R, Feher M, Ban F, Awrey DE, Mao G, Plotnikova O, Hodgson R, Beletskaya I, Mason JM, Luo X, Nadeem V, Wei X, Kiarash R, Madeira B, Huang P, Mak TW, Pan G, Pauls HW..  (2015)  The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent..  J Med Chem,  58  (1): (147-169).  [PMID:25723005]
80. Robles AJ, Peng J, Hartley RM, Lee B, Mooberry SL..  (2015)  Melampodium leucanthum, a source of cytotoxic sesquiterpenes with antimitotic activities..  J Nat Prod,  78  (3): (388-395).  [PMID:25685941]
81. Chen CT, Hsu JT, Lin WH, Lu CT, Yen SC, Hsu T, Huang YL, Song JS, Chen CH, Chou LH, Yen KJ, Chen CP, Kuo PC, Huang CL, Liu HE, Chao YS, Yeh TK, Jiaang WT..  (2015)  Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations..  Eur J Med Chem,  100  (151-161).  [PMID:26081023]
82. Lin XD, Yang HW, Ma S, Li WW, Zhang CH, Wang WJ, Xiang R, Li LL, Yang SY..  (2015)  Discovery of 6-phenylimidazo[2,1-b]thiazole derivatives as a new type of FLT3 inhibitors..  Bioorg Med Chem Lett,  25  (20): (4534-4538).  [PMID:26342867]
83. Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L..  (2015)  Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity..  Bioorg Med Chem,  23  (21): (7000-7006).  [PMID:26455654]
84. Aman W, Lee J, Kim M, Yang S, Jung H, Hah JM..  (2016)  Discovery of highly selective CRAF inhibitors, 3-carboxamido-2H-indazole-6-arylamide: In silico FBLD design, synthesis and evaluation..  Bioorg Med Chem Lett,  26  (4): (1188-1192).  [PMID:26810260]
85. Bavetsias V, Lanigan RM, Ruda GF, Atrash B, McLaughlin MG, Tumber A, Mok NY, Le Bihan YV, Dempster S, Boxall KJ, Jeganathan F, Hatch SB, Savitsky P, Velupillai S, Krojer T, England KS, Sejberg J, Thai C, Donovan A, Pal A, Scozzafava G, Bennett JM, Kawamura A, Johansson C, Szykowska A, Gileadi C, Burgess-Brown NA, von Delft F, Oppermann U, Walters Z, Shipley J, Raynaud FI, Westaway SM, Prinjha RK, Fedorov O, Burke R, Schofield CJ, Westwood IM, Bountra C, Müller S, van Montfort RL, Brennan PE, Blagg J..  (2016)  8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors..  J Med Chem,  59  (4): (1388-1409).  [PMID:26741168]
86. Schiemann K, Mallinger A, Wienke D, Esdar C, Poeschke O, Busch M, Rohdich F, Eccles SA, Schneider R, Raynaud FI, Czodrowski P, Musil D, Schwarz D, Urbahns K, Blagg J..  (2016)  Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore..  Bioorg Med Chem Lett,  26  (5): (1443-1451).  [PMID:26852363]
87. Daydé-Cazals B, Fauvel B, Singer M, Feneyrolles C, Bestgen B, Gassiot F, Spenlinhauer A, Warnault P, Van Hijfte N, Borjini N, Chevé G, Yasri A..  (2016)  Rational Design, Synthesis, and Biological Evaluation of 7-Azaindole Derivatives as Potent Focused Multi-Targeted Kinase Inhibitors..  J Med Chem,  59  (8): (3886-3905).  [PMID:27010810]
88. Schroeder RL, Goyal N, Bratton M, Townley I, Pham NA, Tram P, Stone T, Geathers J, Nguyen K, Sridhar J..  (2016)  Identification of quinones as novel PIM1 kinase inhibitors..  Bioorg Med Chem Lett,  26  (13): (3187-3191).  [PMID:27173800]
89. Kumar V, Guru SK, Jain SK, Joshi P, Gandhi SG, Bharate SB, Bhushan S, Bharate SS, Vishwakarma RA..  (2016)  A chromatography-free isolation of rohitukine from leaves of Dysoxylum binectariferum: Evaluation for in vitro cytotoxicity, Cdk inhibition and physicochemical properties..  Bioorg Med Chem Lett,  26  (15): (3457-3463).  [PMID:27363938]
90. Klaeger S, Heinzlmeir S and Wilhelm M et al.  (2017)  The target landscape of clinical kinase drugs..  Science,  358  (6367):   [PMID:29191878]
91. Chen Y, Zheng Y, Jiang Q, Qin F, Zhang Y, Fu L, He G..  (2017)  Integrated bioinformatics, computational and experimental methods to discover novel Raf/extracellular-signal regulated kinase (ERK) dual inhibitors against breast cancer cells..  Eur J Med Chem,  127  (997-1011).  [PMID:27839788]
92. Shi Y, Park J, Lagisetti C, Zhou W, Sambucetti LC, Webb TR..  (2017)  A triple exon-skipping luciferase reporter assay identifies a new CLK inhibitor pharmacophore..  Bioorg Med Chem Lett,  27  (3): (406-412).  [PMID:28049589]
93. Ma F, Liu P, Lei M, Liu J, Wang H, Zhao S, Hu L..  (2017)  Design, synthesis and biological evaluation of indolin-2-one-based derivatives as potent, selective and efficacious inhibitors of FMS-like tyrosine kinase3 (FLT3)..  Eur J Med Chem,  127  (72-86).  [PMID:28038328]
94. Zhu JY, Cuellar RA, Berndt N, Lee HE, Olesen SH, Martin MP, Jensen JT, Georg GI, Schönbrunn E..  (2017)  Structural Basis of Wee Kinases Functionality and Inactivation by Diverse Small Molecule Inhibitors..  J Med Chem,  60  (18): (7863-7875).  [PMID:28792760]
95. Singh U, Chashoo G, Khan SU, Mahajan P, Nargotra A, Mahajan G, Singh A, Sharma A, Mintoo MJ, Guru SK, Aruri H, Thatikonda T, Sahu P, Chibber P, Kumar V, Mir SA, Bharate SS, Madishetti S, Nandi U, Singh G, Mondhe DM, Bhushan S, Malik F, Mignani S, Vishwakarma RA, Singh PP..  (2017)  Design of Novel 3-Pyrimidinylazaindole CDK2/9 Inhibitors with Potent In Vitro and In Vivo Antitumor Efficacy in a Triple-Negative Breast Cancer Model..  J Med Chem,  60  (23): (9470-9489).  [PMID:29144137]
96. Liu Z, Wang P, Chen H, Wold EA, Tian B, Brasier AR, Zhou J..  (2017)  Drug Discovery Targeting Bromodomain-Containing Protein 4..  J Med Chem,  60  (11): (4533-4558).  [PMID:28195723]
97. Zhao XZ, Hymel D, Burke TR..  (2017)  Enhancing polo-like kinase 1 selectivity of polo-box domain-binding peptides..  Bioorg Med Chem,  25  (19): (5041-5049).  [PMID:28285924]
98. Smith GP, Badolo L, Chell V, Chen IJ, Christensen KV, David L, Daechsel JA, Hentzer M, Herzig MC, Mikkelsen GK, Watson SP, Williamson DS..  (2017)  The design and SAR of a novel series of 2-aminopyridine based LRRK2 inhibitors..  Bioorg Med Chem Lett,  27  (18): (4500-4505).  [PMID:28802631]
99. He L, Li D, Zhang C, Bai P, Chen L..  (2017)  Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC..  Bioorg Med Chem Lett,  27  (17): (4171-4175).  [PMID:28734581]
100. Gege C, Cummings MD, Albers M, Kinzel O, Kleymann G, Schlüter T, Steeneck C, Nelen MI, Milligan C, Spurlino J, Xue X, Leonard K, Edwards JP, Fourie A, Goldberg SD, Hoffmann T..  (2018)  Identification and biological evaluation of thiazole-based inverse agonists of RORγt..  Bioorg Med Chem Lett,  28  (9): (1446-1455).  [PMID:29631962]
101. Malínková V, Řezníčková E, Jorda R, Gucký T, Kryštof V..  (2017)  Trisubstituted purine inhibitors of PDGFRα and their antileukemic activity in the human eosinophilic cell line EOL-1..  Bioorg Med Chem,  25  (24): (6523-6535).  [PMID:29089259]
102. Monastyrskyi A, Nilchan N, Quereda V, Noguchi Y, Ruiz C, Grant W, Cameron M, Duckett D, Roush W..  (2018)  Development of dual casein kinase 1δ/1ε (CK1δ/ε) inhibitors for treatment of breast cancer..  Bioorg Med Chem,  26  (3): (590-602).  [PMID:29289448]
103. Czudor Z, Balogh M, Bánhegyi P, Boros S, Breza N, Dobos J, Fábián M, Horváth Z, Illyés E, Markó P, Sipos A, Szántai-Kis C, Szokol B, Őrfi L..  (2018)  Novel compounds with potent CDK9 inhibitory activity for the treatment of myeloma..  Bioorg Med Chem Lett,  28  (4): (769-773).  [PMID:29329658]
104. Assadieskandar A, Yu C, Maisonneuve P, Liu X, Chen YC, Prakash GKS, Kurinov I, Sicheri F, Zhang C..  (2018)  Effects of rigidity on the selectivity of protein kinase inhibitors..  Eur J Med Chem,  146  (519-528).  [PMID:29407977]
105. Wang Q, Liu F, Qi S, Qi Z, Yan XE, Wang B, Wang A, Wang W, Chen C, Liu X, Jiang Z, Hu Z, Wang L, Wang W, Ren T, Zhang S, Yun CH, Liu Q, Liu J..  (2018)  Discovery of 4-((N-(2-(dimethylamino)ethyl)acrylamido)methyl)-N-(4-methyl-3-((4-(pyridin-3-yl)pyrimidin-2-yl)amino)phenyl)benzamide (CHMFL-PDGFR-159) as a highly selective type II PDGFRα kinase inhibitor for PDGFRα driving chronic eosinophilic leukemia..  Eur J Med Chem,  150  (366-384).  [PMID:29544149]
106. He LJ, Yang DL, Li SQ, Zhang YJ, Tang Y, Lei J, Frett B, Lin HK, Li HY, Chen ZZ, Xu ZG..  (2018)  Facile construction of fused benzimidazole-isoquinolinones that induce cell-cycle arrest and apoptosis in colorectal cancer cells..  Bioorg Med Chem,  26  (14): (3899-3908).  [PMID:29921474]
107. Jiang JK, Huang X, Shamim K, Patel PR, Lee A, Wang AQ, Nguyen K, Tawa G, Cuny GD, Yu PB, Zheng W, Xu X, Sanderson P, Huang W..  (2018)  Discovery of 3-(4-sulfamoylnaphthyl)pyrazolo[1,5-a]pyrimidines as potent and selective ALK2 inhibitors..  Bioorg Med Chem Lett,  28  (20): (3356-3362).  [PMID:30227946]
108. Wang B, Wu J, Wu Y, Chen C, Zou F, Wang A, Wu H, Hu Z, Jiang Z, Liu Q, Wang W, Zhang Y, Liu F, Zhao M, Hu J, Huang T, Ge J, Wang L, Ren T, Wang Y, Liu J, Liu Q..  (2018)  Discovery of 4-(((4-(5-chloro-2-(((1s,4s)-4-((2-methoxyethyl)amino)cyclohexyl)amino)pyridin-4-yl)thiazol-2-yl)amino)methyl)tetrahydro-2H-pyran-4-carbonitrile (JSH-150) as a novel highly selective and potent CDK9 kinase inhibitor..  Eur J Med Chem,  158  (896-916).  [PMID:30253346]
109. Dodo K, Kuboki E, Shimizu T, Imamura R, Magarisawa M, Takahashi M, Tokuhiro T, Yotsumoto S, Asano K, Nakao S, Terayama N, Suda T, Tanaka M, Sodeoka M..  (2019)  Development of a Water-Soluble Indolylmaleimide Derivative IM-93 Showing Dual Inhibition of Ferroptosis and NETosis..  ACS Med Chem Lett,  10  (9): (1272-1278).  [PMID:31531196]
110. Zhang Q, Hu X, Wan G, Wang J, Li L, Wu X, Liu Z, Yu L..  (2019)  Discovery of 3-(((9H-purin-6-yl)amino)methyl)-4,6-dimethylpyridin-2(1H)-one derivatives as novel tubulin polymerization inhibitors for treatment of cancer..  Eur J Med Chem,  184  (111728-111728).  [PMID:31610375]
111. Narayan S, Ramisetti S, Jaiswal AS, Law BK, Singh-Pillay A, Singh P, Amin S, Sharma AK..  (2019)  ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells..  Eur J Med Chem,  161  (456-467).  [PMID:30384048]
112. Osborne J, Birchall K, Tsagris DJ, Lewis SJ, Smiljanic-Hurley E, Taylor DL, Levy A, Alessi DR, McIver EG..  (2019)  Discovery of potent and selective 5-azaindazole inhibitors of leucine-rich repeat kinase 2 (LRRK2) - Part 1..  Bioorg Med Chem Lett,  29  (4): (668-673).  [PMID:30554956]
113. Wang Y, Dou X, Jiang L, Jin H, Zhang L, Zhang L, Liu Z..  (2019)  Discovery of novel glycogen synthase kinase-3α inhibitors: Structure-based virtual screening, preliminary SAR and biological evaluation for treatment of acute myeloid leukemia..  Eur J Med Chem,  171  (221-234).  [PMID:30925338]
114. Abdelaziz AM, Basnet SKC, Islam S, Li M, Tadesse S, Albrecht H, Gerber C, Yu M, Wang S..  (2019)  Synthesis and evaluation of 2'H-spiro[cyclohexane-1,3'-imidazo[1,5-a]pyridine]-1',5'-dione derivatives as Mnk inhibitors..  Bioorg Med Chem Lett,  29  (18): (2650-2654).  [PMID:31362920]
115. Qi B, Zhong L, He J, Zhang H, Li F, Wang T, Zou J, Lin YX, Zhang C, Guo X, Li R, Shi J..  (2019)  Discovery of Inhibitors of Aurora/PLK Targets as Anticancer Agents..  J Med Chem,  62  (17): (7697-7707).  [PMID:31381325]
116. Wang X, Yu C, Wang C, Ma Y, Wang T, Li Y, Huang Z, Zhou M, Sun P, Zheng J, Yang S, Fan Y, Xiang R..  (2019)  Novel cyclin-dependent kinase 9 (CDK9) inhibitor with suppression of cancer stemness activity against non-small-cell lung cancer..  Eur J Med Chem,  181  (111535-111535).  [PMID:31376566]
117. Zhao L, Li Y, Wang Y, Qiao Z, Miao Z, Yang J, Huang L, Tian C, Li L, Chen D, Yang S..  (2019)  Discovery of 4H-Chromen-4-one Derivatives as a New Class of Selective Rho Kinase (ROCK) Inhibitors, which Showed Potent Activity in ex Vivo Diabetic Retinopathy Models..  J Med Chem,  62  (23): (10691-10710).  [PMID:31693351]
118. Jang J, Son JB, To C, Bahcall M, Kim SY, Kang SY, Mushajiang M, Lee Y, Jänne PA, Choi HG, Gray NS..  (2017)  Discovery of a potent dual ALK and EGFR T790M inhibitor..  Eur J Med Chem,  136  (497-510).  [PMID:28528303]
119. Oukoloff K, Coquelle N, Bartolini M, Naldi M, Le Guevel R, Bach S, Josselin B, Ruchaud S, Catto M, Pisani L, Denora N, Iacobazzi RM, Silman I, Sussman JL, Buron F, Colletier JP, Jean L, Routier S, Renard PY..  (2019)  Design, biological evaluation and X-ray crystallography of nanomolar multifunctional ligands targeting simultaneously acetylcholinesterase and glycogen synthase kinase-3..  Eur J Med Chem,  168  (58-77).  [PMID:30798053]
120. Heider F, Ansideri F, Tesch R, Pantsar T, Haun U, Döring E, Kudolo M, Poso A, Albrecht W, Laufer SA, Koch P..  (2019)  Pyridinylimidazoles as dual glycogen synthase kinase 3β/p38α mitogen-activated protein kinase inhibitors..  Eur J Med Chem,  175  (309-329).  [PMID:31096153]
121. Watts E, Heidenreich D, Tucker E, Raab M, Strebhardt K, Chesler L, Knapp S, Bellenie B, Hoelder S..  (2019)  Designing Dual Inhibitors of Anaplastic Lymphoma Kinase (ALK) and Bromodomain-4 (BRD4) by Tuning Kinase Selectivity..  J Med Chem,  62  (5): (2618-2637).  [PMID:30789735]
122. Ikegashira K, Ikenogami T, Yamasaki T, Oka T, Hase Y, Miyagawa N, Inagaki K, Kawahara I, Koga Y, Hashimoto H..  (2019)  Optimization of an azetidine series as inhibitors of colony stimulating factor-1 receptor (CSF-1R) Type II to lead to the clinical candidate JTE-952..  Bioorg Med Chem Lett,  29  (7): (873-877).  [PMID:30755337]
123. Hamilton GL,Chen H,Deshmukh G,Eigenbrot C,Fong R,Johnson A,Kohli PB,Lupardus PJ,Liederer BM,Ramaswamy S,Wang H,Wang J,Xu Z,Zhu Y,Vucic D,Patel S.  (2019)  Potent and selective inhibitors of receptor-interacting protein kinase 1 that lack an aromatic back pocket group..  Bioorg Med Chem Lett,  29  (12.0): (1497-1501).  [PMID:31000154]
124. Alverez CN,Park JE,Toti KS,Xia Y,Krausz KW,Rai G,Bang JK,Gonzalez FJ,Jacobson KA,Lee KS.  (2020)  Identification of a New Heterocyclic Scaffold for Inhibitors of the Polo-Box Domain of Polo-like Kinase 1..  J Med Chem,  63  (22): (14087-14117).  [PMID:33175530]
125. Matheson, Christopher J., Coxon, Christopher R., Bayliss, Richard, Boxall, Kathy, Carbain, Benoit, Fry, Andrew M., Hardcastle, Ian R., Harnor, Suzannah J., Mas-Droux, Corine, Newell, David R., Richards, Mark W., Sivaprakasam, Mangaleswaran, Turner, David, Griffin, Roger J., Golding, Bernard T., Cano, Celine.  (2020)  2-Arylamino-6-ethynylpurines are cysteine-targeting irreversible inhibitors of Nek2 kinase.  RSC Med Chem,  11  (6): (707-731).  [PMID:33479670]
126. Yang J,Chen K,Zhang G,Yang QY,Li YS,Huang SZ,Wang YL,Yang W,Jiang XJ,Yan HX,Zhu JQ,Xiang R,Luo YF,Li WM,Wei YQ,Li LL,Yang SY.  (2018)  Structural optimization and structure-activity relationship studies of N-phenyl-7,8-dihydro-6H-pyrimido[5,4-b][1,4]oxazin-4-amine derivatives as a new class of inhibitors of RET and its drug resistance mutants..  Eur J Med Chem,  143  (1148-1164).  [PMID:29133048]
127. Deng Z,Chen G,Liu S,Li Y,Zhong J,Zhang B,Li L,Huang H,Wang Z,Xu Q,Deng X.  (2020)  Discovery of methyl 3-((2-((1-(dimethylglycyl)-5-methoxyindolin-6-yl)amino)-5-(trifluoro-methyl) pyrimidin-4-yl)amino)thiophene-2-carboxylate as a potent and selective polo-like kinase 1 (PLK1) inhibitor for combating hepatocellular carcinoma..  Eur J Med Chem,  206  (112697-112697).  [PMID:32814244]
128. El-Damasy AK,Jin H,Seo SH,Bang EK,Keum G.  (2020)  Design, synthesis, and biological evaluations of novel 3-amino-4-ethynyl indazole derivatives as Bcr-Abl kinase inhibitors with potent cellular antileukemic activity..  Eur J Med Chem,  207  (112710-112710).  [PMID:32961435]
129. Liang X, Tang S, Liu X, Liu Y, Xu Q, Wang X, Saidahmatov A, Li C, Wang J, Zhou Y, Zhang Y, Geng M, Huang M, Liu H..  (2022)  Discovery of Novel Pyrrolo[2,3-d]pyrimidine-based Derivatives as Potent JAK/HDAC Dual Inhibitors for the Treatment of Refractory Solid Tumors..  J Med Chem,  65  (2.0): (1243-1264).  [PMID:33586434]
130. Bräuninger, A A, Strebhardt, K K and Rübsamen-Waigmann, H H..  (1995)  Identification and functional characterization of the human and murine polo-like kinase (Plk) promoter..  Oncogene,    (2):   [PMID:7478607]
131. Lake, R J RJ and Jelinek, W R WR..  (1993)  Cell cycle- and terminal differentiation-associated regulation of the mouse mRNA encoding a conserved mitotic protein kinase..  Molecular and cellular biology,      [PMID:7902533]
132. Golsteyn, R M RM and 5 more authors..  (1994)  Cell cycle analysis and chromosomal localization of human Plk1, a putative homologue of the mitotic kinases Drosophila polo and Saccharomyces cerevisiae Cdc5..  Journal of cell science,      [PMID:7962193]
133. Hamanaka, R R and 5 more authors..  (1994)  Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase..  Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research,      [PMID:8018557]
134. Holtrich, U U and 6 more authors..  (1994)  Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors..  Proceedings of the National Academy of Sciences of the United States of America,    (1):   [PMID:8127874]
135. Lane, H A HA and Nigg, E A EA..  (1996)  Antibody microinjection reveals an essential role for human polo-like kinase 1 (Plk1) in the functional maturation of mitotic centrosomes..  The Journal of cell biology,      [PMID:8991084]
136. Uchiumi, T T, Longo, D L DL and Ferris, D K DK..  (1997)  Cell cycle regulation of the human polo-like kinase (PLK) promoter..  The Journal of biological chemistry,    (4):   [PMID:9083047]
137. Roshak, A K AK and 5 more authors..  (2000)  The human polo-like kinase, PLK, regulates cdc2/cyclin B through phosphorylation and activation of the cdc25C phosphatase..  Cellular signalling,      [PMID:11202906]
138. Jang, Young-Joo YJ, Ma, Sheng S, Terada, Yasuhiko Y and Erikson, Raymond L RL..  (2002)  Phosphorylation of threonine 210 and the role of serine 137 in the regulation of mammalian polo-like kinase..  The Journal of biological chemistry,    (15):   [PMID:12207013]
139. Wind, Mathias M, Kelm, Olaf O, Nigg, Erich A EA and Lehmann, Wolf D WD..  (2002)  Identification of phosphorylation sites in the polo-like kinases Plx1 and Plk1 by a novel strategy based on element and electrospray high resolution mass spectrometry..  Proteomics,      [PMID:12442251]
140. Yuan, Juping J and 5 more authors..  (2002)  Cooperative phosphorylation including the activity of polo-like kinase 1 regulates the subcellular localization of cyclin B1..  Oncogene,    (28):   [PMID:12447691]
141. Jackman, Mark M, Lindon, Catherine C, Nigg, Erich A EA and Pines, Jonathon J..  (2003)  Active cyclin B1-Cdk1 first appears on centrosomes in prophase..  Nature cell biology,      [PMID:12524548]
142. Walter, Sarah A SA, Cutler, Richard E RE, Martinez, Ricardo R, Gishizky, Mikhail M and Hill, Ronald J RJ..  (2003)  Stk10, a new member of the polo-like kinase kinase family highly expressed in hematopoietic tissue..  The Journal of biological chemistry,    (16):   [PMID:12639966]
143. Nakajima, Hiroyuki H, Toyoshima-Morimoto, Fumiko F, Taniguchi, Eri E and Nishida, Eisuke E..  (2003)  Identification of a consensus motif for Plk (Polo-like kinase) phosphorylation reveals Myt1 as a Plk1 substrate..  The Journal of biological chemistry,    (11):   [PMID:12738781]
144. Casenghi, Martina M and 5 more authors..  (2003)  Polo-like kinase 1 regulates Nlp, a centrosome protein involved in microtubule nucleation..  Developmental cell,      [PMID:12852856]
145. Neef, Rüdiger R and 6 more authors..  (2003)  Phosphorylation of mitotic kinesin-like protein 2 by polo-like kinase 1 is required for cytokinesis..  The Journal of cell biology,    (1):   [PMID:12939256]
146. Elia, Andrew E H AE and 9 more authors..  (2003)  The molecular basis for phosphodependent substrate targeting and regulation of Plks by the Polo-box domain..  Cell,    (3):   [PMID:14532005]
147. Cheng, Kin-Yip KY, Lowe, Edward D ED, Sinclair, John J, Nigg, Erich A EA and Johnson, Louise N LN..  (2003)  The crystal structure of the human polo-like kinase-1 polo box domain and its phospho-peptide complex..  The EMBO journal,    (3):   [PMID:14592974]
148. Andersen, Jens S JS and 5 more authors..  (2003)  Proteomic characterization of the human centrosome by protein correlation profiling..  Nature,    (4):   [PMID:14654843]
149. Lindon, Catherine C and Pines, Jonathon J..  (2004)  Ordered proteolysis in anaphase inactivates Plk1 to contribute to proper mitotic exit in human cells..  The Journal of cell biology,    (19):   [PMID:14734534]
150. Watanabe, Nobumoto N and 6 more authors..  (2004)  M-phase kinases induce phospho-dependent ubiquitination of somatic Wee1 by SCFbeta-TrCP..  Proceedings of the National Academy of Sciences of the United States of America,    (30):   [PMID:15070733]
151. Moshe, Yakir Y, Boulaire, Jérôme J, Pagano, Michele M and Hershko, Avram A..  (2004)  Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome..  Proceedings of the National Academy of Sciences of the United States of America,    (25):   [PMID:15148369]
152. Hansen, David V DV, Loktev, Alexander V AV, Ban, Kenneth H KH and Jackson, Peter K PK..  (2004)  Plk1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1..  Molecular biology of the cell,      [PMID:15469984]
153. Guarguaglini, Giulia G and 5 more authors..  (2005)  The forkhead-associated domain protein Cep170 interacts with Polo-like kinase 1 and serves as a marker for mature centrioles..  Molecular biology of the cell,      [PMID:15616186]
154. Kim, Soo-A SA, Yoon, Jung-Hoon JH, Lee, Sang-Ho SH and Ahn, Sang-Gun SG..  (2005)  Polo-like kinase 1 phosphorylates heat shock transcription factor 1 and mediates its nuclear translocation during heat stress..  The Journal of biological chemistry,    (1):   [PMID:15661742]
155. Fabbro, Megan M and 10 more authors..  (2005)  Cdk1/Erk2- and Plk1-dependent phosphorylation of a centrosome protein, Cep55, is required for its recruitment to midbody and cytokinesis..  Developmental cell,      [PMID:16198290]
156. Niiya, F F, Tatsumoto, T T, Lee, K S KS and Miki, T T..  (2006)  Phosphorylation of the cytokinesis regulator ECT2 at G2/M phase stimulates association of the mitotic kinase Plk1 and accumulation of GTP-bound RhoA..  Oncogene,    (9):   [PMID:16247472]
157. Eldridge, Adam G AG and 5 more authors..  (2006)  The evi5 oncogene regulates cyclin accumulation by stabilizing the anaphase-promoting complex inhibitor emi1..  Cell,    (27):   [PMID:16439210]
158. Kanaji, Shingo S and 8 more authors..  (2006)  Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma..  Oncology,      [PMID:16645325]
159. Qi, Wei W, Tang, Zhanyun Z and Yu, Hongtao H..  (2006)  Phosphorylation- and polo-box-dependent binding of Plk1 to Bub1 is required for the kinetochore localization of Plk1..  Molecular biology of the cell,      [PMID:16760428]
160. Oshimori, Naoki N, Ohsugi, Miho M and Yamamoto, Tadashi T..  (2006)  The Plk1 target Kizuna stabilizes mitotic centrosomes to ensure spindle bipolarity..  Nature cell biology,      [PMID:16980960]
161. Kang, Young H YH and 10 more authors..  (2006)  Self-regulated Plk1 recruitment to kinetochores by the Plk1-PBIP1 interaction is critical for proper chromosome segregation..  Molecular cell,    (3):   [PMID:17081991]
162. Baumann, Christoph C, Körner, Roman R, Hofmann, Kay K and Nigg, Erich A EA..  (2007)  PICH, a centromere-associated SNF2 family ATPase, is regulated by Plk1 and required for the spindle checkpoint..  Cell,    (12):   [PMID:17218258]
163. García-Alvarez, Begoña B, de Cárcer, Guillermo G, Ibañez, Sonia S, Bragado-Nilsson, Elisabeth E and Montoya, Guillermo G..  (2007)  Molecular and structural basis of polo-like kinase 1 substrate recognition: Implications in centrosomal localization..  Proceedings of the National Academy of Sciences of the United States of America,    (27):   [PMID:17307877]
164. Zhang, Y Y and 5 more authors..  (2007)  TTDN1 is a Plk1-interacting protein involved in maintenance of cell cycle integrity..  Cellular and molecular life sciences : CMLS,      [PMID:17310276]
165. Neef, Rüdiger R and 6 more authors..  (2007)  Choice of Plk1 docking partners during mitosis and cytokinesis is controlled by the activation state of Cdk1..  Nature cell biology,      [PMID:17351640]
166. Matsumura, Shigeru S, Toyoshima, Fumiko F and Nishida, Eisuke E..  (2007)  Polo-like kinase 1 facilitates chromosome alignment during prometaphase through BubR1..  The Journal of biological chemistry,    (18):   [PMID:17376779]
167. Kothe, Michael M and 14 more authors..  (2007)  Structure of the catalytic domain of human polo-like kinase 1..  Biochemistry,    (22):   [PMID:17461553]
168. Stegmeier, Frank F and 5 more authors..  (2007)  The tumor suppressor CYLD regulates entry into mitosis..  Proceedings of the National Academy of Sciences of the United States of America,    (22):   [PMID:17495026]
169. Pouwels, Jeroen J and 6 more authors..  (2007)  Shugoshin 1 plays a central role in kinetochore assembly and is required for kinetochore targeting of Plk1..  Cell cycle (Georgetown, Tex.),    (1):   [PMID:17617734]
170. Liu, Lin L, Zhang, Min M and Zou, Ping P..  (2007)  Expression of PLK1 and survivin in diffuse large B-cell lymphoma..  Leukemia & lymphoma,      [PMID:17943598]
171. Salvatore, Giuliana G and 13 more authors..  (2007)  A cell proliferation and chromosomal instability signature in anaplastic thyroid carcinoma..  Cancer research,    (1):   [PMID:17981789]
172. Koida, Nami N and 9 more authors..  (2008)  Inhibitory role of Plk1 in the regulation of p73-dependent apoptosis through physical interaction and phosphorylation..  The Journal of biological chemistry,    (28):   [PMID:18174154]
173. Pohl, Christian C and Jentsch, Stefan S..  (2008)  Final stages of cytokinesis and midbody ring formation are controlled by BRUCE..  Cell,    (7):   [PMID:18329369]
174. Wang, Xiaoxing X and 6 more authors..  (2008)  sSgo1, a major splice variant of Sgo1, functions in centriole cohesion where it is regulated by Plk1..  Developmental cell,      [PMID:18331714]
175. Bandeiras, Tiago M TM and 18 more authors..  (2008)  Structure of wild-type Plk-1 kinase domain in complex with a selective DARPin..  Acta crystallographica. Section D, Biological crystallography,      [PMID:18391401]
176. Soond, Surinder M SM and 5 more authors..  (2008)  p73-mediated transcriptional activity is negatively regulated by polo-like kinase 1..  Cell cycle (Georgetown, Tex.),    (1):   [PMID:18418051]
177. Yamashiro, Shigeko S and 7 more authors..  (2008)  Myosin phosphatase-targeting subunit 1 regulates mitosis by antagonizing polo-like kinase 1..  Developmental cell,      [PMID:18477460]
178. Chan, Eunice H Y EH, Santamaria, Anna A, Silljé, Herman H W HH and Nigg, Erich A EA..  (2008)  Plk1 regulates mitotic Aurora A function through betaTrCP-dependent degradation of hBora..  Chromosoma,      [PMID:18521620]
179. Macůrek, Libor L and 9 more authors..  (2008)  Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery..  Nature,    (4):   [PMID:18615013]
180. Bassermann, Florian F and 5 more authors..  (2008)  The Cdc14B-Cdh1-Plk1 axis controls the G2 DNA-damage-response checkpoint..  Cell,    (25):   [PMID:18662541]
181. Daub, Henrik H and 9 more authors..  (2008)  Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle..  Molecular cell,    (8):   [PMID:18691976]
182. Lee, Yoon-Jin YJ and 6 more authors..  (2008)  HSF1 as a mitotic regulator: phosphorylation of HSF1 by Plk1 is essential for mitotic progression..  Cancer research,    (15):   [PMID:18794143]
183. Sharlow, Elizabeth R ER and 9 more authors..  (2008)  Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone..  The Journal of biological chemistry,    (28):   [PMID:18829454]
184. Zhu, Hui H, Coppinger, Judith A JA, Jang, Chang-Young CY, Yates, John R JR and Fang, Guowei G..  (2008)  FAM29A promotes microtubule amplification via recruitment of the NEDD1-gamma-tubulin complex to the mitotic spindle..  The Journal of cell biology,    (1):   [PMID:19029337]
185. Fu, Zheng Z and 7 more authors..  (2008)  Plk1-dependent phosphorylation of FoxM1 regulates a transcriptional programme required for mitotic progression..  Nature cell biology,      [PMID:19160488]
186. Jang, Chang-Young CY, Coppinger, Judith A JA, Seki, Akiko A, Yates, John R JR and Fang, Guowei G..  (2009)  Plk1 and Aurora A regulate the depolymerase activity and the cellular localization of Kif2a..  Journal of cell science,    (1):   [PMID:19351716]
187. Wolfe, Benjamin A BA, Takaki, Tohru T, Petronczki, Mark M and Glotzer, Michael M..  (2009)  Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF complex to initiate cleavage furrow formation..  PLoS biology,    (5):   [PMID:19468300]
188. Burkard, Mark E ME and 10 more authors..  (2009)  Plk1 self-organization and priming phosphorylation of HsCYK-4 at the spindle midzone regulate the onset of division in human cells..  PLoS biology,    (5):   [PMID:19468302]
189. Yang, Xiaoming X and 6 more authors..  (2009)  Plk1-mediated phosphorylation of Topors regulates p53 stability..  The Journal of biological chemistry,    (10):   [PMID:19473992]
190. Zhang, Xiaoyan X and 7 more authors..  (2009)  Sequential phosphorylation of Nedd1 by Cdk1 and Plk1 is required for targeting of the gammaTuRC to the centrosome..  Journal of cell science,    (1):   [PMID:19509060]
191. Svendsen, Jennifer M JM and 6 more authors..  (2009)  Mammalian BTBD12/SLX4 assembles a Holliday junction resolvase and is required for DNA repair..  Cell,    (10):   [PMID:19596235]
192. Yun, Sang-Moon SM and 21 more authors..  (2009)  Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1..  Nature structural & molecular biology,      [PMID:19597481]
193. Li, Hongchang H and 5 more authors..  (2010)  Polo-like kinase 1 phosphorylation of p150Glued facilitates nuclear envelope breakdown during prophase..  Proceedings of the National Academy of Sciences of the United States of America,    (17):   [PMID:20679239]
194. Dunsch, Anja K AK, Linnane, Emily E, Barr, Francis A FA and Gruneberg, Ulrike U..  (2011)  The astrin-kinastrin/SKAP complex localizes to microtubule plus ends and facilitates chromosome alignment..  The Journal of cell biology,    (21):   [PMID:21402792]
195. Liu, Fa and 8 more authors..  (2011)  Serendipitous alkylation of a Plk1 ligand uncovers a new binding channel..  Nature chemical biology,    (17):   [PMID:21765407]
196. Liu, Ting T and 5 more authors..  (2011)  Phosphorylation of right open reading frame 2 (Rio2) protein kinase by polo-like kinase 1 regulates mitotic progression..  The Journal of biological chemistry,    (21):   [PMID:21880710]
197. Ikeda, Masanori M, Chiba, Shuhei S, Ohashi, Kazumasa K and Mizuno, Kensaku K..  (2012)  Furry protein promotes aurora A-mediated Polo-like kinase 1 activation..  The Journal of biological chemistry,    (10):   [PMID:22753416]
198. Van Damme, Petra P and 15 more authors..  (2012)  N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB..  Proceedings of the National Academy of Sciences of the United States of America,    (31):   [PMID:22814378]
199. Yeh, Ting-Yu TY and 7 more authors..  (2013)  Dynactin helps target Polo-like kinase 1 to kinetochores via its left-handed beta-helical p27 subunit..  The EMBO journal,    (3):   [PMID:23455152]
200. Beck, Jochen J and 11 more authors..  (2013)  Ubiquitylation-dependent localization of PLK1 in mitosis..  Nature cell biology,      [PMID:23455478]
201. Zhu, Mei M and 7 more authors..  (2013)  MISP is a novel Plk1 substrate required for proper spindle orientation and mitotic progression..  The Journal of cell biology,    (18):   [PMID:23509069]
202. Shen, Minhong M and 5 more authors..  (2013)  Centrosomal protein FOR20 is essential for S-phase progression by recruiting Plk1 to centrosomes..  Cell research,      [PMID:24018379]
203. Metzger, Thibaud T, Kleiss, Charlotte C and Sumara, Izabela I..  (2013)  CUL3 and protein kinases: insights from PLK1/KLHL22 interaction..  Cell cycle (Georgetown, Tex.),    (15):   [PMID:24067371]
204. Pagan, Julia K JK and 7 more authors..  (2015)  Degradation of Cep68 and PCNT cleavage mediate Cep215 removal from the PCM to allow centriole separation, disengagement and licensing..  Nature cell biology,      [PMID:25503564]
205. Douglas, Pauline P and 5 more authors..  (2015)  Phosphorylation of SAF-A/hnRNP-U Serine 59 by Polo-Like Kinase 1 Is Required for Mitosis..  Molecular and cellular biology,      [PMID:25986610]
206. Zhang, Boyan B and 9 more authors..  (2017)  DAZ-interacting Protein 1 (Dzip1) Phosphorylation by Polo-like Kinase 1 (Plk1) Regulates the Centriolar Satellite Localization of the BBSome Protein during the Cell Cycle..  The Journal of biological chemistry,    (27):   [PMID:27979967]
207. Lee, Kyung Ho KH and 17 more authors..  (2018)  Phosphorylation of human enhancer filamentation 1 (HEF1) stimulates interaction with Polo-like kinase 1 leading to HEF1 localization to focal adhesions..  The Journal of biological chemistry,    (19):   [PMID:29191835]
208. Perez, Yonatan Y and 7 more authors..  (2019)  Mutations in the microtubule-associated protein MAP11 (C7orf43) cause microcephaly in humans and zebrafish..  Brain : a journal of neurology,    (1):   [PMID:30715179]

Solution Calculators

Privacy Policy Website Terms of Use Return policy Terms and Conditions of Sale Cookie Policy Sales Policy
Products are chemical reagents for research use only and are not intended for human use. We do not sell to patients.
Copyright © 2023-present Aladdin Scientific Corp . All rights reserved.